The Use of LIPID Formulations of Amphotericin B in Cancer Patients

Meunier F. , Aoun M. , Bitar N. Candidemia in immunocompromised patients. Clin Infect Dis. 1992; 14(suppl 1): S120–S125.

Morrison V.A. , Haake R.J. , Weisdorf D.J. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med. 1994; 96: 497–503.

Fairfield A.G. Infections in the cancer patient. In: DeVita V.T. Jr , Hellman S. , Rosenberg S.A. , eds. Principles and Practice of Oncology. 5th ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1997: 2659–2704.

Schimpff S.C. Infections in the cancer patient: diagnosis, prevention, and treatment. In: Mandell G.L. , Bennett J.E. , Dolin R. , eds. Principles and Practice of Infectious Diseases. 4th ed. New York, NY: Churchill Livingstone; 1995: 2675–2686.

Anaissie E.J. , Darouiche R.O. , Abi-Said D. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis. 1996; 23: 964–972.

Bennett J.E. Antifungal agents. In: Mandell G.L. , Bennett J.E. , Dolin R. , eds. Principles and Practice of Infectious Diseases. 4th ed. New York, NY: Churchill Livingstone; 1995: 401–410.

Prentice A.G. , Warnock D.W. , Johnson S.A. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J Antimicrob Chemother. 1995; 36: 657–663.

Prentice A.G. , Warnock D.W. , Johnson S.A. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother. 1994; 34: 247–252.

Gallis H.A. , Drew R.H. , Pickard W.W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990; 12: 308–329.

Hughes W.T. , Armstrong D. , Bodey G.P. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis. 1997; 25: 251–273.

Anaissie E.J. , White M.H. , Uzun O. Amphotericin B lipid complex versus amphotericin B for treatment of invasive candidiasis. Presented at 35th ICAC, 1995.

White M.H. , Anaissie E.J. , Kusne S. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis. 1997; 24: 635–642.

Hiemenz J.W. , Walsh T.J. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis. 1996; 22(suppl 2): S133–S144.

Abelcet (Amphotericin B Lipid Complex) Product Information. The Liposome Company. Princeton, NJ. December 1996.

Amphotec (Amphotericin B Choles-teryl Sulfate Complex for Injection) Product Information. Sequus Pharmaceuticals. Men-lo Park, Calif. October 1996.

AmBisome (Amphotericin B Liposome for Injection) Product Information. Fujisawa USA Inc. Deerfield, IL. August 1997.

Mehta J. Do variations in molecular structure affect the clinical efficacy and safety of lipid based amphotericin B preparations? Leuk Res. 1997; 21: 183–188.

Groll A. , Giri N. , Gonzalez C. Penetration of lipid formulations of amphotericin B into cerebrospinal fluid and brain tissue. 37th ICAC, 1997. Abstract A90.

Lister J. Amphotericin B lipid complex in the treatment of invasive mycoses: the North American experience. Eur J Haematol. 1996; 56(suppl 57): 18–23.

Walsh T.J. , Whitcomb P. , Piscitelli S. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother. 1997; 41: 1944–1948.

Liposome Company Drug Information Request. Unpublished data. June 2, 1998.

Bowden R.A. , Cays M. , Gooley T. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis. 1996; 173: 1208–1215.

Oppenheim B.A. , Herbrecht R. , Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis. 1995; 21: 1145–1153.

White M.H. , Bowden R.A. , Sandler E. Amphotericin B colloidal dispersion vs amphotericin B in the empiric treatment of febrile neutropenic patients. Blood. 1996; 88(suppl 1): 302a.

Mills W. , Chopra R. , Linch D.C. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol. 1994; 86: 754–760.

Prentice H.G. , Hann I.M. , Herbrecht R. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997; 98: 711–718.

Prescription product listings. Drug Topics Red Book. 102nd ed. Montvale, NJ: Medical Economics Co; 1998: 134, 150, 159.

Amphotericin B For Injection, USP. Product information. Genesia Laboratories, Ltd. Irvine, Calif. January 1995.